HomeAI · summaries
Storia in 8 fonti
AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Detailed data show Pfizer’s monthly obesity drug continues to show potential
Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.
- ·
New data may cast doubt on competitiveness of Boehringer’s obesity drug
Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.
